Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.7
3.2
Journals
Life
Special Issues
Influenza Vaccines and Antibody Therapies
share announcement

Influenza Vaccines and Antibody Therapies

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: closed (16 December 2022) | Viewed by 5860

Special Issue Editors

Prof. Dr. Lei Deng

E-Mail Website1 Website2
Guest Editor
Hunan Provincial Key Laboratory of Medical Virology, Institute of Pathogen Biology and Immunology of College of Biology, Hunan University, Changsha 410082, China
Interests: influenza virus; coronavirus; vaccinology; adaptive immunity; universal vaccine; antigen modification; cross-reactive antibody; antibody affinity maturation; B and T cell epitope; nanoparticle vaccine
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Yao-Qing Chen

E-Mail Website
Guest Editor
Key Laboratory of Tropical Disease Control (Sun Yat-sen University), Ministry of Education, School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen 510275, China
Interests: influenza virus; coronavirus; universal vaccine; monoclonal antibody; neutralizing antibody; cross-reactive antibody; broad spectrum antibody; antibody affinity maturation; BCR ; single cell sequence; hemagglutinin, neuraminidase
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to announce that the Special Issue “Influenza vaccines and antibody therapies” will open in January 2022. This Special Issue will accept original articles on the latest clinical or experimental research on influenza vaccines and antibodies and the exploration of the immune protection mechanisms. The submissions of research articles, reviews and commentary pieces is welcomed.

Human influenza is a contagious disease mainly caused by influenza A or B viruses. Influenza A viruses circulate in several animal species and occasionally cause global pandemics. In the context of the current SARS-CoV-2 pandemic, influenza prevention and treatment have more significance in lowering the risk of respiratory virus co-infection. Vaccination is still the most effective approach to control the spread of influenza. However, the current vaccines provide limited immune protection against antigenically matching influenza viruses, and the vaccine composition needs to be updated nearly every year. Influenza vaccines comprising amino acid- or conformation-conserved epitopes would in principle offer full protection against antigenically distant influenza viruses. Immuno-focusing strategies and protein structure-based manipulation guide the design and development of next-generation universal influenza vaccines. Conserved T-cell epitopes elicit cross-reactive cellular immunity and offer infection-permissive protection by efficiently clearing infected host cells. The lack of reliable methods to quantify cellular immune protection effectiveness impedes T-cell epitope-based vaccine development. In addition, it is also important that influenza vaccines must provide long-lasting specific immune protection. Extending the longevity of the protective antibody memory requires an interdisciplinary approach for its solution.

Prof. Dr. Lei Deng
Prof. Dr. Yao-Qing Chen
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Influenza virus
  • Antigen modification
  • Universal influenza vaccine
  • Broadly neutralizing antibody
  • Antibody therapy
  • Antibody affinity maturation
  • Adjuvant
  • Nanoparticle vaccine
  • Protein glycosylation
  • B- and T-cell epitopes
  • Immunogenicity
  • Antigenicity
  • Long-lasting immunity

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 3224 KiB  
Article
Sublingual Vaccination with Live Influenza Virus Induces Better Protection Than Oral Immunization in Mice
by Jie Mao, Gi-Deok Eom, Keon-Woong Yoon, Hae-Ji Kang, Ki-Back Chu and Fu-Shi Quan
Life 2022, 12(7), 975; https://doi.org/10.3390/life12070975 - 29 Jun 2022
Cited by 2 | Viewed by 1417
Abstract
Both sublingual (SL) and oral vaccine administration modalities are convenient, easy, and safe. Here, we have investigated the differences in vaccine efficacy that are induced by oral and sublingual immunization with live influenza virus (A/Hong Kong/1/1968, H3N2) in mice. Intranasally administering a lethal [...] Read more.
Both sublingual (SL) and oral vaccine administration modalities are convenient, easy, and safe. Here, we have investigated the differences in vaccine efficacy that are induced by oral and sublingual immunization with live influenza virus (A/Hong Kong/1/1968, H3N2) in mice. Intranasally administering a lethal dose of the influenza virus resulted in the deaths of the mice, whereas viral replication in the lungs did not occur upon SL or oral administration. At 30 days post-immunization through the SL or oral route, the mice were intranasally challenge-infected with the lethal dose of the homologous influenza virus. Both SL and oral immunizations with the influenza virus elicited significantly higher levels of virus-specific IgG and IgA antibody responses, as well as HAI titers in the sera. Upon challenge infection, the SL immunization elicited higher levels of pulmonary IgG antibody and CD8+ T cell responses than the oral immunization. Enhanced splenic germinal center B (GC B) and B cell proliferation were also detected from the SL immunization, both of which were significantly greater than those of the oral immunization. Importantly, compared to oral immunization, significantly lessened lung viral loads and bodyweight reductions were observed from the SL immunization and these parameters contributed to prolonging the survival of the immunized mice. These results indicate that both SL and oral administration could be effective routes in inducing protective immunity against influenza virus infection, with SL immunization being the better of the two delivery routes. Full article
(This article belongs to the Special Issue Influenza Vaccines and Antibody Therapies)
►▼ Show Figures

Figure 1

Review

Jump to: Research

19 pages, 546 KiB  
Review
Status and Challenges for Vaccination against Avian H9N2 Influenza Virus in China
by Jinze Dong, Yong Zhou, Juan Pu and Litao Liu
Life 2022, 12(9), 1326; https://doi.org/10.3390/life12091326 - 27 Aug 2022
Cited by 13 | Viewed by 3324
Abstract
In China, H9N2 avian influenza virus (AIV) has become widely prevalent in poultry, causing huge economic losses after secondary infection with other pathogens. Importantly, H9N2 AIV continuously infects humans, and its six internal genes frequently reassort with other influenza viruses to generate novel [...] Read more.
In China, H9N2 avian influenza virus (AIV) has become widely prevalent in poultry, causing huge economic losses after secondary infection with other pathogens. Importantly, H9N2 AIV continuously infects humans, and its six internal genes frequently reassort with other influenza viruses to generate novel influenza viruses that infect humans, threatening public health. Inactivated whole-virus vaccines have been used to control H9N2 AIV in China for more than 20 years, and they can alleviate clinical symptoms after immunization, greatly reducing economic losses. However, H9N2 AIVs can still be isolated from immunized chickens and have recently become the main epidemic subtype. A more effective vaccine prevention strategy might be able to address the current situation. Herein, we analyze the current status and vaccination strategy against H9N2 AIV and summarize the progress in vaccine development to provide insight for better H9N2 prevention and control. Full article
(This article belongs to the Special Issue Influenza Vaccines and Antibody Therapies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop